Hydroxyurea and its effects on quality of life in sickle cell anemia
Author Information
Author(s): Samir K Ballas, Franca B Barton, Myron A Waclawiw, Paul Swerdlow, James R Eckman, Charles H Pegelow, Mabel Koshy, Bruce A Barton, Duane R Bonds
Primary Institution: Cardeza Foundation, Department of Medicine, Jefferson Medical College, Philadelphia PA, USA
Hypothesis
Does hydroxyurea treatment improve the quality of life in patients with sickle cell anemia?
Conclusion
Hydroxyurea treatment improves some aspects of quality of life in adult patients with moderate-to-severe sickle cell anemia.
Supporting Evidence
- Hydroxyurea reduced painful sickle cell episodes and hospitalizations.
- Patients with high fetal hemoglobin response showed better quality of life improvements.
- Quality of life measures were assessed using validated tools like SF-36.
Takeaway
Hydroxyurea can help people with sickle cell anemia feel better in some ways, especially if they respond well to the treatment.
Methodology
The study involved 299 patients in a randomized, double-blind trial assessing quality of life measures over two years.
Potential Biases
Potential bias due to the selection of patients with moderate-to-severe disease who may have irreversible effects.
Limitations
The study's findings may not apply to patients with less severe disease or those who did not respond to hydroxyurea.
Participant Demographics
49% male, 51% female; age distribution: 18–29 (51%), 30–39 (39%), 40–49 (9%), >=50 (1%).
Statistical Information
P-Value
p<0.001
Confidence Interval
99%
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website